GRN Holding Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GRNF research report →
Price Chart
About the company
GRN Holding Corporation currently possesses no significant business operations, and its primary objective is to finalize a merger with another enterprise. In the past, the company concentrated its efforts on the exploration and development of gold resources. Established in 2010, it was initially named Discovery Gold Corporation until its rebranding as GRN Holding Corporation in September 2019.
- CEO
- Donald J. Steinberg
- IPO
- 2012
- HQ
- Seattle, WA, US
Get TickerSpark's AI analysis on GRNF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.37M
- P/E
- 0.36
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.01
- EV/EBITDA
- -0.25
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -4.65%
- ROIC
- -6.31%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-3,216-111.5%
- Op Income
- $-56,800
- Net Income
- $-56,804-1005.1%
- EPS
- $-0.00-666.7%
- OCF Growth
- -628.8%
- FCF Growth
- -628.7%
- 52W High
- $0.20
- 52W Low
- $0.01
- 50D MA
- $0.02
- 200D MA
- $0.06
- Beta
- -1.33
- RSI (14)
- 52
- Avg Volume
- 153.59K
No earnings-call transcripts are available for GRNF yet.
- Free Float
- 0.0%
- Shares Outstanding
- 35.09M
- Float Shares
- 0
of shares held by institutions
1 13F filers
Our GRNF coverage
Recent articles, reports, and earnings notes.
No research on GRNF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GRNF report →Denali Therapeutics: 'Strong Buy' On AVLAYAH Approval And End Of 2026 FTD-GRN Data
seekingalpha.com · May 27
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
globenewswire.com · Jan 10
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
globenewswire.com · Oct 24
GRN Holding Corp Announces Joint Venture With One World Legends on Global Distribution of Cannabis
globenewswire.com · Aug 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.